小剂量美罗华治疗原发免疫性血小板减少症的临床疗效观察  

Efficacy of Low-dose Rituximab for Patients with Immune Trombocytopenia

作　　者：刘月波[1] 周泽平[1] 杨红[1] 姚锦[1] 张铀[1] 

机构地区：[1]昆明医科大学第二附属医院,云南昆明650101

出　　处：《昆明医科大学学报》2012年第11期99-101,共3页Journal of Kunming Medical University

摘　　要：目的观察小剂量美罗华治疗免疫性血小板减少症(ITP)的疗效.方法选择ITP患者20例,用小剂量美罗华治疗(剂量为100 mg/次,每周1次,连续4周),观察血小板计数及不良反应.结果总反应率(OR)和完全反应率(CR)分别为70%,95%CI 45.8%～88.1%和45%,95%CI 23.2%～68.6%,中位反应时间为38(16～92)d.结论小剂量美罗华可作为对常规治疗无效患者一种有效的治疗.Objective To evaluate the efficacy of low-dose rituximab on immune thrombocytopenia（ITP）.Method Twenty patients were given 100mg rituximab weekly for four weeks,the platelet count and adverse events were observed.Results Overall and complete response（OR and CR）rates were 70% and 45%,respectively.The median time to response was 38（16-92） day.Conclusion The low-dose rituximab regimens（100 mg weekly for four weeks）is effective for patients with ITP.

关 键 词：小剂量 美罗华 疗效 免疫性血小板减少症 

分 类 号：R554[医药卫生—血液循环系统疾病]